BS EN ISO 5840-1:2021
$215.11
Cardiovascular implants. Cardiac valve prostheses – General requirements
Published By | Publication Date | Number of Pages |
BSI | 2021 | 88 |
This document is applicable to heart valve substitutes intended for implantation and provides general requirements. Subsequent parts of the ISO 5840 series provide specific requirements.
This document is applicable to newly developed and modified heart valve substitutes and to the accessory devices, packaging, and labelling required for their implantation and for determining the appropriate size of the heart valve substitute to be implanted.
ISO 5840-1 outlines an approach for verifying/validating the design and manufacture of a heart valve substitute through risk management. The selection of appropriate qualification tests and methods are derived from the risk assessment. The tests can include those to assess the physical, chemical, biological, and mechanical properties of heart valve substitutes and of their materials and components. The tests can also include those for preclinical in vivo evaluation and clinical evaluation of the finished heart valve substitute.
ISO 5840-1 defines operational conditions for heart valve substitutes.
ISO 5840-1 furthermore defines terms that are also applicable to ISO 5840-2 and ISO 5840-3.
ISO 5840-1 does not provide requirements specific to homografts, tissue engineered heart valves (e.g. valves intended to regenerate in vivo), and heart valve substitutes designed for implantation in circulatory support devices. Some of the provisions of ISO 5840-1 can be applied to valves made from human tissue that is rendered non-viable.
A rationale for the provisions of ISO 5840-1 is given in Annex A.
PDF Catalog
PDF Pages | PDF Title |
---|---|
2 | undefined |
4 | European foreword Endorsement notice |
7 | Foreword |
8 | Introduction |
9 | 1 Scope 2 Normative references |
10 | 3 Terms and definitions |
23 | 4 Abbreviations 5 Fundamental requirements |
24 | 6 Device description 6.1 General 6.2 Intended use 6.3 Design inputs 6.3.1 Operational specifications |
25 | 6.3.2 Performance specifications 6.3.3 Implant procedure 6.3.4 Packaging, labelling, and sterilization |
26 | 6.4 Design outputs 6.5 Design transfer (manufacturing verification/validation) 6.6 Risk management 7 Design verification and validation 7.1 General requirements 7.2 In vitro assessment 7.2.1 General |
27 | 7.2.2 Test conditions, sample selection and reporting requirements |
28 | 7.2.3 Material property assessment |
29 | 7.2.4 Hydrodynamic performance assessment 7.2.5 Structural performance assessment |
31 | 7.2.6 Design- or procedure-specific testing 7.2.7 Device MRI compatibility 7.2.8 Simulated use 7.2.9 Human factors/usability assessment 7.2.10 Implant thrombogenic and haemolytic potential assessment |
32 | 7.3 Preclinical in vivo evaluation 7.4 Clinical investigations |
33 | Annex A (informative) Rationale for the provisions of ISO 5840-1 |
36 | Annex B (normative) Packaging |
37 | Annex C (normative) Product labels, instructions for use, and training |
40 | Annex D (normative) Sterilization |
41 | Annex E (normative) In vitro test guidelines for paediatric devices |
45 | Annex F (informative) Corrosion assessment |
48 | Annex G (informative) Echocardiographic protocol |
50 | Annex H (informative) Assessment of implant thrombogenic and haemolytic potential |
61 | Annex I (informative) Guidelines for hydrodynamic performance characterization by steady flow testing |
68 | Annex J (normative) Durability testing |
76 | Annex K (informative) Fatigue assessment |
81 | Annex L (normative) Clinical investigation endpoints for heart valve replacement devices |
84 | Bibliography |